By Dr. Laura Tennant
Ancient cultures across the globe utilized Cannabis sativa for a selection of medicinal and recreational purposes and quite a few examples have been found by archaeologists and historians in the course of the examination of ancient documents and artefacts. For instance, the Ancient Egyptian Ebers Papyrus is a single of the most full preserved health-related documents, dating back to the eighteenth century BC. It documents the components and preparation of medicinal treatments utilized by the ancient Egyptians and involves a quantity of recipes containing Cannabis sativa for ailments such as inflammation and discomfort. In Ancient China, legend has it that the Emperor Shen Neng (c. 2737 B.C) prescribed teas produced from medicinal cannabis for a selection of illnesses and the initially documented use of cannabis as an analgesic was recorded in 140-208 in China by the surgeon Hua Toa, who gave his individuals powdered extracts of the plant combined with wine prior to surgery.
In the context of cancer, while the prescribed use of medicinal cannabis for cancer is fairly new to Oncologists in existing instances, its origins date back thousands of years. In 1993, the mummified remains of a young lady, estimated to be at least two,500 years old, had been located in the Altai Mountains of Siberia. Amongst the things placed in her burial chamber, archaeologists located a pouch of Cannabis, identified to be utilized as an analgesic in ancient instances. Additional investigation of the remains by MRI revealed that the lady had been suffering from sophisticated metastatic breast cancer and so the researchers hypothesize that the lady utilized cannabis to offer relief from the discomfort and symptoms of her illness.
Today´s Clinical Practise
The Pharmaceutical market are establishing drugs primarily based on active elements of Cannabis sativa and two drugs are presently authorized in various nations for cancer connected discomfort: Drobinol (synthetic Δ9-tetrahydrocannabinol -THC- the most psychoactive cannabinoid located in cannabis) and Sativex (a blend of the leaf and flower of two strains of cannabis, cultivated with controlled proportions of THC and Cannabidiol). Not surprisingly, most of the clinical trial proof supporting the use of cannabis for cancer individuals comes from the improvement procedure of these drugs rather than from trials with the botanical and considering that clinicians rely heavily on clinical trial information, some stay sceptical about the efficacy of medicinal cannabis. Study extra.
This year, in two peer-reviewed publications directed at health-related pros, Oncologist Dr D.I. Abrams at the University of San Francisco produced a compelling argument for the inclusion of medicinal cannabis in modern day clinical cancer care protocols. He argued that while the proof from clinical trials of the botanical in controlled situations frequently lacking or inconclusive, encounter from clinical practise clearly demonstrates that it assists individuals coping with cancer and improves their top quality of life. In certain he supports the use of medicinal cannabis for relief from chemotherapy-induced neuropathic discomfort, insomnia, nausea and loss of appetite when traditional remedies have failed and when side effects of pharmaceutical outweigh the rewards of the drugs. To access the publications, click the following hyperlink.
What does the future hold?
Provided the proof from clinical practice, there is a clear need to have for information from comprehensive clinical research of medicinal cannabis to assistance its use in cancer individuals for alleviating the symptoms connected with cancer. Having said that, the botanical may well hold the crucial to extra than just symptomatic relief. There is a expanding physique of proof from pre-clinical analysis in cell and animal models that recommend that some of the active elements of cannabis may well have direct anti-tumour activity. For instance, in laboratory research of glioma cells, cannabinoids had been shown to induce cell death (apoptosis) and quit cell development (proliferation). These activities had been also observed in rat and mouse models and reductions in tumour sizes had been recorded. The complicated molecular mechanisms behind the cannabinoid activity are nonetheless becoming unravelled, though the CB1 receptor is believed to be involved. This analysis is now advancing towards clinical research (see publication). There are various other examples of fascinating preclinical information in other tumour forms the analysis is reviewed in detail in the following publication. This analysis is nonetheless at early stages and demands to be translated into humans, even so, the future of cannabis in the field of Oncology surely appears promising.
If you or a loved a single would like extra data on health-related cannabis licensing, register with Plants Not Tablets applying the promo code NOW16, e-mail [email protected] or contact 1-844-473-6060.
Cannabis for Cancer Sufferers: Previous, Present and Future February 4th, 2019